Skip to main content

Symposia 6 - The WHO System for Reporting Soft Tissue Cytopathology: The Rationale, Structure, Categories and Application in

Tracking # 20-1038386

$99999.00

There are no ratings for this course

Learn more
CE Broker Reporting Reported automatically
Method Computer-Based Training

Course overview

The WHO System for Reporting Soft Tissue Cytopathology has been developed and a book written and published by an expert editorial board of cytopathologists brought together by the WHO publisher IARC in a joint program with the International Academy of Cytology over the last eighteen months. The Reporting System is based on six well defined categories each of which will have a risk of malignancy and recommendation for further diagnostic management. The aim is to standardize the approach to reporting soft tissue cytopathology and improve communication with clinicians and ultimately improve patient care. The key diagnostic cytopathological features have been established by consensus for each lesion or neoplasm, and a discussion of the cytopathological differential diagnosis and the appropriate use of ancillary testing are presented.

Subject areas

This course counts toward the state boards and subject areas below.

Florida Board of Clinical Laboratory Personnel

Clinical Laboratory Director

2h General (Cytology)

Clinical Laboratory Supervisor

2h General (Cytology)

Clinical Laboratory Technician

2h General (Cytology)

Clinical Laboratory Technologist

2h General (Cytology)

Public Health Director

2h General (Cytology)

Public Health Supervisor

2h General (Cytology)

Public Health Technologist

2h General (Cytology)

Disclosure statements

The faculty, committee members, Executive Board and staff who are in position to control the content of this activity are required to disclose to the ASC and to learners any financial relationships that have occurred within the last 24 months with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ASC has reviewed the disclosures and mitigated all relevant financial relationships.

The following individuals have reported financial relationships:

Michael Berry, SCT(ASCP)MBCM: Stockholder-Hologic

Oscar Lin, MD, PhD: Consultant – Hologic and Jansen

Liron Pantanowitz, MD: Consultant – Hamamatsu, Advisory Board for Ibex

Martha B. Pitman, MD, FIAC: Consultant – Adenocyte, LLC

Donna K. Russell, MEd, CT(ASCP), HT(ASCP): Advisory Board – Hologic Scientific

Christopher J. VandenBussche, MD, PhD: Ad hoc advisory board panel and Consultant – Roche

Paul VanderLaan, MD, PhD: Consultant – Gala Therapeutics